Abstract CAR T-cell therapy is a popular topic of discussion in and out of the scientific community. Already with multiple therapies FDA-approved for certain blood cancers, focus has rightly shifted toward FDA approval for solid tumor indications. Yet, advancing past clinical trials to FDA approval has yet to occur and has proved challenging. Of course, multiple factors are at play as to why, but we aim to use-in house expertise to elucidate one, namely CAR T-cell tumor infiltration and tissue migration and surveillance efficacy. Migration is a central parameter ignored in traditional 2D cytotoxicity assays, but there is no tumor cell killing by T cells if there is no T cell migration. We developed a novel first-of-its-kind organoid-based 3D cytotoxicity assay using multicompartment organoids and the most abundant extracellular matrix protein in human organs, collagen. We suspend solid tumor organoids in the center of CAR T-cell/collagen gel mixtures that are solidified then imaged in intervals in the span of two weeks by live-cell time-lapse reflection/fluorescence confocal microscopy, after which standard luciferase-based readouts of quantitative specific lysis is determined. Our assay allows high-resolution tracking of CAR T-cell 3D movements through collagen fibers surrounding solid tumor organoids to determine their random and directional migration as well as their surveillance and infiltration of solid tumor organoids. We will describe the differences between currently in clinical trial mesothelin-specific CAR T-cell therapies that differ in their scFv, hinge, transmembrane, and costimulatory domains; and comparing alongside the traditional 2D luciferase-based cytotoxicity assay, we will underline how 3D migration and infiltration around and into mesothelin-expressing ovarian cancer cell organoids allow the determination of CAR T-cell therapy efficacy of different CAR T clones in a lab’s arsenal for a given solid tumor through migration, infiltration, and subsequent cytotoxic capacity that is absent in traditional 2D cytotoxicity assays. CAR T-cell therapy vector design and cloning can thus be tuned for optimal migration and infiltration using our novel 3D cytotoxicity assay. Citation Format: Adrian Johnston, Zeqi Wan, Tina Chen, Yeongseo Lim, Cameron Lee, Wenxuan Du, Jude Philip, Denis Wirtz. Novel 3D cytotoxicity assay to assess the impact of chimeric antigen receptor (CAR) domain design on the tumor infiltration and cytotoxicity efficacy of CAR T-cell therapies for solid tumors. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4710.
Read full abstract